A Phase Ib/II Study of Ibrutinib in Combination With GA101 - Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients Over 65 Years of Age or With Comorbidities That Preclude the Use of Chemotherapy Based Treatment. GA101+Ibrutinib

Trial Profile

A Phase Ib/II Study of Ibrutinib in Combination With GA101 - Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients Over 65 Years of Age or With Comorbidities That Preclude the Use of Chemotherapy Based Treatment. GA101+Ibrutinib

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Obinutuzumab
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Dec 2016 Results (n=9) of preliminary analysis assessing safety and tolerability was presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 01 Dec 2015 Planned End Date changed from 1 Mar 2019 to 1 Nov 2018, as reported by ClinicalTrials.gov.
    • 01 Dec 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Nov 2017, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top